Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Noninvasive Method Captures Circulating Tumor Cells

By Labmedica International staff writers
Posted on 24 Jul 2014
Print article
Image:  The Becton Dickinson fluorescent activated cell sorter FACScan (Photo courtesy of the Albert Einstein College of Medicine).
Image: The Becton Dickinson fluorescent activated cell sorter FACScan (Photo courtesy of the Albert Einstein College of Medicine).
A clinically proven, noninvasive fluorescence virus-guided capture system of human colorectal circulating tumor cells (CTCs) from blood samples for genetic testing has been introduced.

This noninvasive companion diagnostics is important for personalized targeted cancer therapy because current CTC detection strategies mainly depend on epithelial cell-surface markers, and the presence of heterogeneous populations of CTCs with epithelial and/or mesenchymal characteristics may pose obstacles to the detection of CTCs.

Scientists at Okayama University (Japan) developed a new approach to capture live CTCs among millions of peripheral blood leukocytes using a green fluorescent protein (GFP)-expressing attenuated adenovirus, in which the telomerase promoter regulates viral replication. The team used different cell lines and a recombinant adenovirus.

Immunochemical staining was performed on cells seeded on tissue culture chamber slides. The cells were labelled with primary mouse antibodies for various receptors and were analyzed using single cell flow cytometry (FACS; Becton Dickinson, Mountain View, CA, USA). DNA was extracted from CTC models and clinical samples and gene mutation analysis was carried out by direct sequencing and the sequence of each gene was analyzed with an ABI PRISM 3100 Genetic Analyzer (Life Technologies; Carlsbad, CA, USA).

The blood samples obtained from eight patients with gene-mutated colorectal cancers were analyzed by the replication competent adenovirus OBP-401-based CTC capture system and by allele-specific blocker polymerase chain reaction (ASB-PCR) technology. In preliminary experiments, the number of GFP-positive cells at the P3 gate was less than 10 cells in some clinical blood samples and, therefore, they performed ASB-PCR analysis using GFP-positive cells at the P2 gate. Among the eight blood samples from patients with various stages of colorectal cancer, the same gene mutations as in the primary tumors were detected in the CTCs of two patients with advanced colorectal cancer.

The authors concluded that they have established a telomerase-dependent biological CTC capture system for genotyping of epithelial, mesenchymal, and epithelial-mesenchymal transition (EMT)-induced types of CTCs using telomerase-specific replication-competent adenovirus variant OBP-401 and fluorescent activated cell sorting (FACS) analysis. This technology facilitates the surveillance of genetic alterations in viable CTCs in patients with cancer. The study was published on July 8, 2014, in the journal Gut.

Related Links:

Okayama University
Becton Dickinson
Life Technologies



Print article

Channels

Clinical Chemistry

view channel
Image: Dried blood spots are used to screen newborns for a number of rare inherited conditions. A new dried blood spot screening test has been developed for Niemann-Pick type C, a rare neurodegenerative condition that usually is not diagnosed until after damage to brain cells has begun (Photo courtesy of Washington University School of Medicine).

Newborn Screening Test Developed For Deadly Neurological Disorder

A newborn screening test has been introduced that identifies infants with Niemann-Pick disease type C, an often fatal condition in which cholesterol builds up and eventually destroys brain cells.... Read more

Genetic Tests

view channel
Image: The BioMek FXP automation workstation (Photo courtesy of Beckman Coulter).

Innovative Gene Testing Technology Finds Cancer Risks

A new method has been developed for identifying mutations and prioritizing variants in breast and ovarian cancer genes, which will not only reduce the number of possible variants for doctors to investigate,... Read more

Pathology

view channel
Image: A photomicrograph of an abnormal Pap smear showing changes consistent with Human Papilloma Virus (HPV) and Mild Dysplasia. Note the irregular perinuclear cytoplasmic clearing, which is the key characteristic of identifying HPV visually on a Pap smear (Photo courtesy of Dr. Cynthia D Booth, MD).

Combining Two Diagnostic Tests Drastically Reduces Cancer Miss Rates

The Papanicolaou (Pap) test is recommended for women between 21 and 65 years old as a screening test for cervical cancer. Women 30 and older who are negative on co-testing may wait as long as five years... Read more

Industry News

view channel

R-Biopharm and Merck Partner on Companion Diagnostics

R-Biopharm AG (Darmstadt, Germany) and Merck KGaA (Darmstadt, Germany) have entered into an agreement that constitutes their first collaboration, which will initially focus on developing and launching companion diagnostics. Companion diagnostics play a central role in personalized medicine by helping to find specific... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.